{"entity":{"id":"nct02122146","kind":"trial","name":"A Study Of PF-06664178 In Patients With Advanced Solid Tumors","aka":[],"tldr":"This study tests TROP-2-directed treatment; the registry reports that it is terminated.","summary":"The registry lists NCT02122146 as terminated, last updated 2018-02-19. Enrolment is 31 actual participants. Interventions: PF-06664178. Primary measures include First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD); Number of Patients With All-Causality Treatment-Emergent Adverse Events(TEAEs) [Part 2 & 3]. The registry reason for stopping is: The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results. Results are posted in the registry.","status":"withdrawn","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT02122146","url":"https://clinicaltrials.gov/study/NCT02122146"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["pf-06664178"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02122146","phase":"1","setting":"A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors","sponsor":"Pfizer","started":"2014-08","startedType":"actual","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02122146/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"pf-06664178","kind":"drug","name":"PF-06664178","route":"/drugs/pf-06664178/"}]}}